"Jan. 4, 2013 -- A new study from Australia may offer a new way of identifying people at risk of glaucoma years before vision loss happens.
Glaucoma is a leading cause of blindness. But because vision damage often occurs gradually, mos"...
Methazolamide is indicated in the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where lowering the intraocular pressure is desired before surgery.
DOSAGE AND ADMINISTRATION
The effective therapeutic dose administered varies from 50mg to 100mg 2 or 3 times daily. The drug may be used concomitantly with miotic and osmotic agents.
Methazolamide tablets, USP for oral administration are available as:
25mg: Round, white, unscored tablets debossed GG78 on one side and plain on the reverse side, and supplied as:
NDC 0781-1072-01 bottles of 100
NDC 0781-1072-10 bottles of 1000
50mg: Round, white, scored tablets debossed GG181 on one side and plain on the reverse side, and supplied as:
NDC 0781-1071-01 bottles of 100
NDC 0781-1071-10 bottles of 1000
Store at 20°-25°C (68°-77°F) (see USP Controlled Room Temperature).
Dispense in a tight, light-resistant container.
Rev. 01-2007. Sandoz Inc. Princeton, NJ 08540. FDA Rev date: n/aThis monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 9/2/2008
Additional Methazolamide Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.